Nova Biomedical Executive and Leadership Team

Francis Manganaro, the Chief Executive Officer at Nova Biomedical, directs the company's overarching strategic vision and operational execution. Manganaro guides the development and commercialization of advanced analytical instruments and consumables, focusing on the biopharmaceutical and clinical markets. This leadership role involves steering Nova Biomedical's commitment to enhancing patient care and accelerating biopharmaceutical development through innovative in vitro diagnostic devices. Overseeing global operations, the Chief Executive Officer ensures alignment with corporate objectives and market demands. Manganaro's strategic direction supports the company's expansion and reinforces its position as a leader in critical care blood gas analyzers and cell culture monitoring systems. The executive's focus remains on driving technological advancements and maintaining the company's reputation for quality and reliability in the medical device sector. Francis Manganaro actively engages with key stakeholders to foster growth and innovation across all business units.

Byron Selman, the President & Chief Executive Officer at Nova Biomedical, spearheads the company's strategic direction and global market expansion. Selman drives the innovation and commercialization of Nova Biomedical's advanced analytical instruments and in vitro diagnostic devices, serving both biopharmaceutical and clinical sectors. This executive leadership role encompasses overseeing the company's commitment to improving patient care and expediting biopharmaceutical research through state-of-the-art technology. Byron Selman ensures operational excellence across the organization, from manufacturing to customer service, reinforcing Nova Biomedical's reputation for quality. The President & Chief Executive Officer's vision guides the development of critical care blood gas analyzers, point-of-care meters, and cell culture monitoring systems. Selman's leadership fosters a culture of continuous improvement and technological advancement, positioning Nova Biomedical for sustained growth in the competitive medical device industry. Byron Selman actively cultivates strategic partnerships to enhance market reach and product development.

Susan Hanlon, the Chief Financial Officer at Nova Biomedical, directs all financial operations and strategic financial planning. Hanlon manages the company's fiscal health, overseeing budgeting, forecasting, and financial reporting to support Nova Biomedical's growth in the medical device sector. This critical role involves ensuring financial compliance and optimizing resource allocation for the development and commercialization of advanced analytical instruments. The Chief Financial Officer works closely with other executive leaders to align financial strategies with the company's mission of enhancing patient care and accelerating biopharmaceutical development. Susan Hanlon's expertise is vital in managing investments in innovative technologies, including critical care blood gas analyzers and cell culture monitoring systems. Hanlon provides financial oversight for global operations, ensuring profitability and sustainable expansion. The Chief Financial Officer's guidance supports strategic decision-making across all departments, reinforcing Nova Biomedical's market position.

Louise Borrelli, the Senior Vice President & Chief Financial Officer at Nova Biomedical, oversees the company's comprehensive financial strategy and management. Borrelli directs financial planning, accounting, and reporting functions, ensuring fiscal integrity and supporting the commercialization of Nova Biomedical's advanced analytical instruments and consumables. This executive position is integral to guiding the financial aspects of enhancing patient care and accelerating biopharmaceutical development through innovative diagnostic devices. The Senior Vice President & Chief Financial Officer collaborates with executive leadership to allocate capital effectively for research and development, particularly for critical care blood gas analyzers and point-of-care meters. Louise Borrelli's financial acumen supports global operational efficiency and strategic growth initiatives. Borrelli ensures adherence to financial regulations and drives initiatives to optimize profitability and shareholder value. The Senior Vice President & Chief Financial Officer plays a key part in securing funding for technological advancements and market expansion.

Michelle Buonopane, the Chief Human Resources Officer at Nova Biomedical, leads all human capital strategies and organizational development initiatives. Buonopane is responsible for cultivating a high-performance culture that supports Nova Biomedical's mission of advancing patient care and biopharmaceutical development through innovative medical devices. This role encompasses talent acquisition, employee relations, compensation and benefits, and leadership development across the organization. The Chief Human Resources Officer ensures that HR policies align with the company's strategic objectives and foster an environment conducive to innovation in areas like critical care blood gas analyzers and cell culture monitoring systems. Michelle Buonopane drives initiatives to attract, retain, and develop top talent, crucial for the company's continued success in the global medical device market. Buonopane's leadership ensures a robust and engaged workforce, essential for manufacturing and commercializing cutting-edge technology. The Chief Human Resources Officer champions employee well-being and professional growth.